Angeliq Hormone Therapy Action Date Expected In Fourth Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
A late 2005 approval would come nearly four years after Schering AG filed the Angeliq NDA. Expected fourth quarter action date indicates company will submit CMC data by June.
You may also be interested in...
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Berlex' Angeliq Approved, Will Launch In Mid-2006
The hormone therapy launch will be delayed to allow for physician education and to give the company time to consider internal resource issues as well as near-term pipeline opportunities, Berlex said.
Berlex' Angeliq Is "Approvable"; More Manufacturing Data Needed
The company anticipates a 2005 approval for the hormone replacement therapy for the lowest dose submitted. The firm is also touting a potential antihypertensive effect with Angeliq for higher doses.